This article is a commentary on:
GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response
Andre De Souza1
Fabio A. Tavora2
Devalingam Mahalingam3Pamela N. Munster4
Howard P. Safran1Wafik S. El-Deiry1,5
Benedito A. Carneiro1*- 1Division of Hematology/Oncology, Lifespan Cancer Institute, Warren Alpert Medical School of Brown University, Providence, RI, United States
- 2Argos Laboratory, Fortaleza, Brazil
- 3Division of Hematology/Oncology, Northwestern University, Chicago, IL, United States
- 4Department of Medicine (Hematology/Oncology), Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, United States
- 5Department of Pathology and Laboratory Medicine, Alpert Medical School of Brown University, Providence, RI, United States
by Rudd, C. E. (2020) Front. Immunol. 11:1638. doi: 10.3389/fimmu.2020.01638
We read with interest the insightful manuscript by Christopher E. Rudd highlighting the potential of Glycogen Synthase Kinase-3 (GSK-3) inhibitors for the treatment of SARS-CoV2 (1). The manuscript describes the GSK-3-mediated phosphorylation of key serine residues in SARS-CoV2 nucleocapsid proteins essential for viral replication. These results coupled with preclinical evidence demonstrating the role of GSK-3 in the modulation of innate and adaptive immune responses support the author's hypothesis that GSK-3 inhibitors could be investigated as a potential treatment for COVID-19 infection. GSK-3 small-molecule inhibitors and GSK-3 siRNA reduced PD-1 expression, increased CD8 + T cell function, and enhanced viral clearance in models of herpes (MHV-68) and lymphocytic choriomeningitis (LCMV-C13) viral infections (2). The increased T cell function induced by GSK-3 inhibition resulted in anti-tumor activity comparable with the effects observed with anti-PD-1 monoclonal antibodies in animal models of metastatic melanoma and lymphoma (3). The therapeutic relevance of GSK-3 inhibition is also suggested by studies utilizing animal models of hemorrhagic shock showing that GSK-3β inhibition dampens liver and renal dysfunction by upregulation of anti-inflammatory IL-10 and down-regulation of IL-12p40 and IL-6, a cytokine implicated in the cytokine release syndrome observed in patients with severe SARS-CoV2 (4). GSK-3β inhibition also attenuates the systemic inflammatory response (SIR) in models of sepsis and ischaemia/reperfusion injury by modulating NF-kB-induced inflammatory response (5–8). These findings have potential implication to SIR and the frequent disseminated intravascular vascular coagulopathy observed during the infection with SARS-CoV2. GSK-3β inhibition also decreased mRNA expression of IL-1β, IL-6, and inducible NO synthase (iNOS) in a model of lipopolysaccharide (LPS) mediated inflammation (9).
Dr. Rudd discusses the therapeutic potential of specific GSK-3 inhibitors (i.e., SB216763, tideglusib) and proposes lithium as a GSK-3β inhibitor to consider for clinical trials, an available oral drug with known toxicity profile. However, lithium has a narrow therapeutic index and is significant less potent than other small-molecule GSK-3β inhibitors in clinical development (10, 11). For instance, the potent and selective ATP-competitive GSK-3β inhibitor 9-ING-41 has advanced to the clinic with preliminary results from ongoing clinical trials involving patients with advanced malignancies demonstrating an excellent safety profile devoid of myelosuppressive and immunosuppressive effects. We have recently presented the initial data from an ongoing phase I/II clinical trial of 9-ING-41 administered as monotherapy or combined with several chemotherapy regimens at the annual meeting of the American Society of Clinical Oncology (NCT03678883). The study has enrolled over 200 patients with advanced malignancies and completed cohorts with monotherapy and combination with various standard chemotherapy regimens without attributable Grade 3 or 4 serious adverse events (12). Of particular relevance to a potential COVID-19 study, 9-ING-41 is not associated with myelosuppression of any degree and there has been no evidence of increased infection or any opportunistic/unusual infections even in patients with extensive prior cytotoxic therapy. A complete response was documented in a patient with BRAF V600E metastatic melanoma previously treated with dabrafenib/trametinib and nivolumab, including resolution of brain metastases. Evidence of durable responses and prolonged treatment duration among patients with pancreatic cancer receiving 9-ING-41 plus gemcitabine/nab-paclitaxel and endometrial cancer receiving 9-ING-41 plus carboplatin/paclitaxel has supported the recent activation of a phase 2 study investigating the former regimen in the front-line treatment of metastatic pancreatic cancer with other Phase 2 studies in preparation. In addition to its anti-cancer activity, 9-ING-41 also reduced pulmonary fibrosis and improved pulmonary function in models of TGF-β and bleomycin pulmonary fibrosis (13, 14). This anti-fibrotic activity supported the clinical development and ongoing clinical trial of 9-ING-41 in patients with advanced myelofibrosis (NCT04218071). Considering the likely high global burden of fibrotic lung disease following the pandemic, GSK-3β inhibition with 9-ING-41 could also have a favorable impact in reducing the lung sequelae from COVID-19 infection. Recent autopsy studies from China, Italy and US have demonstrated marked fibrotic lung disease in patients who suffered from the COVID-19 (15–17). Results from in vitro and xenograft models of ovarian cancer also demonstrated that 9-ING-41 was more active than lithium and other ATP-competitive inhibitors such as SB216763 (the compound utilized in the experiments showing the enhancement of T cell function) (10). While ongoing studies are evaluating the immune modulatory effects of 9-ING-41 in T cell function, experiments in prostate cancer cell lines showed that 9-ING-41 regulated the expression of PD-L1 (18). Based on 9-ING-41's established safety profile and pre-clinical potent anti-fibrotic activity aligned with the robust preclinical rationale for GSK-3β blockade outlined elegantly by Dr. Rudd, we believe that this novel GSK-3β inhibitor merits urgent consideration as an investigational therapy for patients with clinically significant COVID-19 infection.
Author Contributions
All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1. Rudd CE. GSK-3 inhibition as a therapeutic approach against SARs CoV2: dual benefit of inhibiting viral replication while potentiating the immune response. Front Immunol. (2020) 11:1638. doi: 10.3389/fimmu.2020.01638
2. Taylor A, Harker JA, Chanthong K, Stevenson PG, Zuniga EI, Rudd CE. Glycogen synthase kinase 3 inactivation drives T-bet-mediated downregulation of co-receptor PD-1 to enhance CD8(+) cytolytic T cell responses. Immunity. (2016) 44:274–86. doi: 10.1016/j.immuni.2016.01.018
3. Taylor A, Rothstein D, Rudd CE. Small-molecule inhibition of PD-1 transcription is an effective alternative to antibody blockade in cancer therapy. Cancer Res. (2018) 78:706–17. doi: 10.1158/0008-5472.CAN-17-0491
4. Jellestad L, Fink T, Pradarutti S, Kubulus D, Wolf B, Bauer I, et al. Inhibition of glycogen synthase kinase (GSK)-3-beta improves liver microcirculation and hepatocellular function after hemorrhagic shock. Eur J Pharmacol. (2014) 724:175–84. doi: 10.1016/j.ejphar.2013.12.029
5. Dugo L, Collin M, Allen DA, Patel NS, Bauer I, Mervaala EM, et al. GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit Care Med. (2005) 33:1903–12. doi: 10.1097/01.ccm.0000178350.21839.44
6. Martin M, Rehani K, Jope RS, Michalek SM. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol. (2005) 6:777–84. doi: 10.1038/ni1221
7. Dugo L, Abdelrahman M, Murch O, Mazzon E, Cuzzocrea S, Thiemermann C. Glycogen synthase kinase-3beta inhibitors protect against the organ injury and dysfunction caused by hemorrhage and resuscitation. Shock. (2006) 25:485–91. doi: 10.1097/01.shk.0000209545.29671.31
8. Cuzzocrea S, Mazzon E, Esposito E, Muia C, Abdelrahman M, Di Paola R, et al. Glycogen synthase kinase-3beta inhibition attenuates the development of ischaemia/reperfusion injury of the gut. Intensive Care Med. (2007) 33:880–93. doi: 10.1007/s00134-007-0595-1
9. Huang WC, Lin YS, Wang CY, Tsai CC, Tseng HC, Chen CL, et al. Glycogen synthase kinase-3 negatively regulates anti-inflammatory interleukin-10 for lipopolysaccharide-induced iNOS/NO biosynthesis and RANTES production in microglial cells. Immunology. (2009) 128:e275–86. doi: 10.1111/j.1365-2567.2008.02959.x
10. Hilliard TS, Gaisina IN, Muehlbauer AG, Gaisin AM, Gallier F, Burdette JE. Glycogen synthase kinase 3beta inhibitors induce apoptosis in ovarian cancer cells and inhibit in-vivo tumor growth. Anticancer Drugs. (2011) 22:978–85. doi: 10.1097/CAD.0b013e32834ac8fc
11. Sahin I, Eturi A, De Souza A, Pamarthy S, Tavora F, Giles FJ, et al. Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses. Cancer Biol Ther. (2019) 20:1047–56. doi: 10.1080/15384047.2019.1595283
12. Carneiro BA, Cavalcante L, Bastos BR, Powell SF, Ma WW, Sahebjam S, et al. Phase I study of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory tumors. J Clin Oncol. (2020) 38(Suppl.):abstr 3507. doi: 10.1200/JCO.2020.38.15_suppl.3507
13. Ding L, Madamsetty VS, Kiers S, Alekhina O, Ugolkov A, Dube J, et al. Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to chemotherapy by abrogating the TopBP1/ATR-mediated DNA damage response. Clin Cancer Res. (2019) 25:6452–62. doi: 10.1158/1078-0432.CCR-19-0799
14. Jeffers A, Qin W, Owens S, Koenig KB, Komatsu S, Giles FJ, et al. Glycogen synthase kinase-3beta inhibition with 9-ING-41 attenuates the progression of pulmonary fibrosis. Sci Rep. (2019) 9:18925. doi: 10.1038/s41598-019-55176-w
15. Ducloyer M, Gaborit B, Toquet C, Castain L, Bal A, Arrigoni PP, et al. Complete post-mortem data in a fatal case of COVID-19: clinical, radiological and pathological correlations. Int J Legal Med. (2020). doi: 10.1007/s00414-020-02390-1. [Epub ahead of print].
16. Schwensen HF, Borreschmidt LK, Storgaard M, Redsted S, Christensen S, Madsen LB. Fatal pulmonary fibrosis: a post-COVID-19 autopsy case. J Clin Pathol. (2020). doi: 10.1136/jclinpath-2020-206879. [Epub ahead of print].
17. Zhang T, Sun LX, Feng RE. [Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease 2019]. Zhonghua Jie He He Hu Xi Za Zhi. (2020) 43:496–502. doi: 10.3760/cma.j.cn112147-20200311-00312
18. Tavora F, Lotan T, Alves M, Zhou L, Amin A, Arunasalam N, et al. Glycogen synthase kinase-3β expression in prostate cancer (PCa) correlates with aggressive pathological features and its blockade with 9-ING-41 inhibits viability of PCa cell lines. In: American Association for Cancer Research (AACR) Annual Meeting 2020, abstract 2959, San Diego (2020).
Keywords: glycogen synthase kinase-3 (GSK3), glycogen synthase kinase-3 (GSK-3) inhibitor, COVID, COVID-19, 9-ING-41, GSK-3b inhibitor, GSK-3 inhibitor, SARS-CoV21
Citation: De Souza A, Tavora FA, Mahalingam D, Munster PN, Safran HP, El-Deiry WS and Carneiro BA (2020) Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response. Front. Immunol. 11:595289. doi: 10.3389/fimmu.2020.595289
Received: 15 August 2020; Accepted: 08 September 2020;
Published: 19 October 2020.
Edited by:
Kjetil Taskén, Oslo University Hospital, NorwayReviewed by:
Christopher E. Rudd, Université de Montréal, CanadaChristoph Wülfing, University of Bristol, United Kingdom
Copyright © 2020 De Souza, Tavora, Mahalingam, Munster, Safran, El-Deiry and Carneiro. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Benedito A. Carneiro, benedito_carneiro@brown.edu